Quantitative parameters comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in patients with liver malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210902004

Enrollment

Registered

2021-09-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

quantitative parameters tumour detection rate 68Ga-FAPI-46, 18F-FDG, Fibroblast activating protein, Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, quantitative

Interventions

Patients with hepatocellular carcinoma (HCC),Patients with cholangiocarcinoma (CCA)

Diagnostic,Diagnostic

hepatocellular carcinoma (HCC),cholangiocarcinoma (CCA)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with diagnosed or suspected liver malignancies who underwent 68Ga-FAPI-46 PET/CT with spot liver PET/MRI and 18F-FDG PET/CT between September 2020 and June 2021

Exclusion criteria

Exclusion criteria: Secondary malignancy

Design outcomes

Primary

Measure	Time frame
quantitative parameters 1 hour after injection Automatic	—

Secondary

Measure	Time frame
Detection rate 1 hour after injection Visual analysis	—

Countries

Thailand

Contacts

Public ContactDheeratama Siripongsatian

National Cyclotron and PET Centre

dheeratama.sir@cra.ac.th0809262298

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026